Relay Therapeutics, Inc.
RLAYHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Relay Therapeutics, Inc. focuses on Biotechnology services and products. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Valued at $3.98B, RLAY is a mid-cap name in its sector. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
Market Cap
$3.98B
Beta
1.73
P/E (TTM)
—
P/E (Fwd)
-11.14
EPS (TTM)
$-1.55
EPS (Fwd)
$-1.63
ROE
-36.8%
ROA
-22.9%
Cash
$910.9M
Total Debt
$30.7M
Free CF
-$119.2M
52W Change
165.0%
Annual Financials
Cash vs Debt
Where RLAY stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RLAY finished 0.67% below its 150-day moving average ($16.39) and 12.43% above its 200-day moving average ($14.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RLAY overbought or oversold?
At the October 19, 2026 close, RLAY's RSI(14) was 40.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $910.9M in cash comfortably exceeding the $30.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$119.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -36.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.4M (2022) to $15.4M (2025), reflecting a 1012% increase over the period.
Relay Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Relay Therapeutics, Inc. and its sector.